PMID- 35117730
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Serum levels of microRNA-21 and microRNA-10a can predict long-term prognosis in 
      laryngeal cancer patients: a multicenter study.
PG  - 3680-3690
LID - 10.21037/tcr-20-1758 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) ranks as the second most 
      common subtype of squamous cell sarcoma (SCC) of the head and neck. In clinical 
      practice, more tools are required to assist doctors in identifying patients who 
      are at risk of poor prognosis at an early stage. Many studies have shown that 
      microRNA-21 plays an important role in LSCC. MicroRNA-10a has also been found to 
      be differentially expressed in squamous cell carcinomas of the head and neck. 
      This study aimed to test whether circulating microRNA-21 and microRNA-10a could 
      serve as prognostic predictors for patients with LSCC. METHODS: Between May 2009 
      and Jan 2015, laryngeal cancer patients who were treated at three medical centers 
      were enrolled based on inclusion and exclusion criteria. Baseline blood samples 
      were obtained before surgery, chemotherapy, or radiotherapy. MicroRNA array was 
      used to detect the microRNAs that were differently expressed between the LSCC 
      patients and healthy controls. The serum levels of selected microRNAs were tested 
      in each patient using qRT-PCR. Clinical information was acquired from the 
      patients' clinic or in-hospital records and all of the patients were followed-up. 
      RESULTS: A total of 236 patients (average age, 59.4+/-10.7 years; male, 223; 33.5% 
      with supraglottic LSCC, and 66.5% with glottis LSCC) were enrolled into the final 
      analysis. MicroRNA array showed that the serum level of microRNA-21 was higher 
      and that of microRNA-10a was lower in the LSCC patients compared with the healthy 
      controls. Patients at T I/II stage, N0 stage, M0 stage had lower serum level of 
      microRNA-21 and higher serum level of microRNA-10a. Serum level of microRNA-21 
      and microRNA-10a both differed significantly between patients with LSCC of well, 
      moderate and poor differentiation. Cox proportional hazards model revealed that T 
      stage, N stage, M stage, age, and ratio of serum level of microRNA-21 and 
      microRNA-10a were risk factors associated with 5-year survival rate in patients 
      with LSCC. Kaplan Meier survival analysis revealed that lower baseline ratio of 
      serum level of microRNA-21 and microRNA-10a predict better 5 years survival. The 
      receiver-operating characteristic curve demonstrated the ratio had a good ability 
      to discriminate patients survive at the end of five years follow-up, with an area 
      under the curve (AUC) of 0.8965 (95% CI: 0.7849-0.9811). CONCLUSIONS: The serum 
      levels of microRNA-21 and microRNA-10a are associated with long-term prognosis in 
      laryngeal cancer patients. Lower serum level of microRNA-21 and higher serum 
      level of microRNA-10a predict better prognosis in LSCC patients.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Gao, Shan
AU  - Gao S
AD  - Department of Otolaryngology-Head and Neck Surgery, Zigong Fourth People's 
      Hospital, Zigong 643000, China.
FAU - Xu, Qin
AU  - Xu Q
AD  - Department of Otolaryngology-Head and Neck Surgery, Zigong Fourth People's 
      Hospital, Zigong 643000, China.
FAU - Zhou, Yongbin
AU  - Zhou Y
AD  - Department of Otolaryngology-Head and Neck Surgery, Zigong Fourth People's 
      Hospital, Zigong 643000, China.
FAU - Yi, Qingchuan
AU  - Yi Q
AD  - Department of Otolaryngology-Head and Neck Surgery, Zigong Fourth People's 
      Hospital, Zigong 643000, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797749
OTO - NOTNLM
OT  - laryngeal cancer
OT  - microRNA-10a
OT  - microRNA-21
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-1758). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/05/01 00:00
MHDA- 2020/05/01 00:01
PMCR- 2020/05/01
CRDT- 2022/02/04 05:51
PHST- 2020/02/19 00:00 [received]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2022/02/04 05:51 [entrez]
PHST- 2020/05/01 00:00 [pubmed]
PHST- 2020/05/01 00:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - tcr-09-05-3680 [pii]
AID - 10.21037/tcr-20-1758 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 May;9(5):3680-3690. doi: 10.21037/tcr-20-1758.